10.25 USD
▲+0.04+1.38%
盘后 10.00 -1.09%
2026-08-03
市值
$203.23M
市盈率
—
EPS
-2.66
股息率
—
52 周区间
9.69 – 22.55
成交量
276.93K
Beta
1.01
目标价
21.83
52W 低 9.6952W 高 22.55
价格走势
公司简介
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that...